An Open Label Study of SC-007 in Subjects With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
At a glance
- Drugs SC-007 (Primary)
- Indications Colorectal cancer; Gastric cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 25 Apr 2018 Status changed from recruiting to discontinued due to benefit/risk imbalance
- 27 Sep 2017 Planned End Date changed from 14 Jul 2021 to 28 Jul 2021.
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.